Research programme: cyclin-dependent kinase inhibitors - AstraZeneca

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - AstraZeneca

Alternative Names: AZ-5576; AZD 5597

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies
  • Discontinued Cancer

Most Recent Events

  • 19 May 2016 Discontinued (AZD 5597) - Preclinical for Cancer in United Kingdom (Parenteral) because AstraZeneca is focusing on other candidate
  • 16 Apr 2016 Preclinical trials in Haematological malignancies in USA (PO) prior to April 2016
  • 16 Apr 2016 Pharmacodynamics data from preclinical trials in Haematological malignancies presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top